Nimotop Inhibitor CAS No. 66085-59-4

Cat. No.	Name	Size	Price	Add Cart
KI0658	Nimotop	50 mg	$154

Chemical Characteristic

Product Name	Nimotop
Synonyms	Nimodipine
CAS No.	66085-59-4
Molecular Weight	418.44
Formula	C₂₁H₂₆N₂O₇
Chemical Structure

Biological activities

Nimotop is a dihydropyridine calcium channel blocker. The IC50 of nimotop is 14.9 nM against calcium channel. Nimotop possesses partition coefficients with a Kp of 187.^[1] Nimotop inhibits contraction and rhythmic activity with an IC50 of 0.08 nM.^[2] Nimotop blocks the internal calcium elevation in chronically depolarized rat cerebellar granule neurons with an IC50 of 0.45 nM.^[3] In rats and baboons with middle cerebral artery occlusion, nimotop reduces neurological deficits without an increase in intracranial pressure or brain edema. Nimotop also improve memory in brain-damaged or old rats, restore sensorimotor function and abnormal walking patterns of old rats, and accelerate acquisition of associative learning in aging rabbits.^[4] Nimotop dose-dependently decreases the DA metabolite 3-methoxytyramine (3-MT) in striatum and the limbic region. Nimotop markedly reduces the accumulation of 3-MT induced by pargyline. In addition, nimotop decreases concentrations of DA and homovanillic acid (HVA) in the limbic region but not in striatum.^[5]

Protocols

Nimotop is dissolved in polyxoyethylated castor oil.^[5]

References

[1] Yiu Sh, et al.Synthesis of valproate, valerate, and 1-methyl-1, 4-dihydropyridyl-3-carbonyloxy ester derivatives of Hantzsch 1,4-dihydropyridines as potential prodrugs and their evaluation as calcium channel antagonist and anticonvulsant agents. Drug Development Research, 1999, 48(1): 26-37. [2] Godfraind T, et al. Calcium antagonists and vasoconstrictor effects in intracerebral microarterioles. Stroke. 1990, 21(12 Suppl): IV59-63. 閵嗏偓閵嗏偓 [3] Marchetti C, et al. High affinity block by nimodipine of the internal calcium elevation in chronically depolarized rat cerebellar granule neurons. Neurosci Lett. 1996, 207(2): 77-80. 閵嗏偓閵嗏偓 [4] Scriabine A, et al. Pharmacological basis for the use of nimodipine in central nervous system disorders. FASEB J. 1989, 3(7): 1799-1806. 閵嗏偓閵嗏偓 [5] Pileblad E, et al. In vivo effects of the Ca²⁺-antagonist nimodipine on dopamine metabolism in mouse brain. J Neural Transm. 1986, 66(3-4): 171-187. 閵嗏偓閵嗏偓

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.